Cancer-associated coagulation disorders
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Diagnosis and treatment of paraneoplastic coagulation disorders are a challenge in daily practice. While prophylactic anticoagulation to prevent venous thromboembolism (VTE) is standard of care in all surgical and acutely ill medical cancer patients, particularly careful evaluation of risks and benefits using validated risk assessment models is required during outpatient chemotherapy. Low-molecular-weight heparin and direct oral factor Xa inhibitors are available to treat established cancer-associated VTE, adhering to algorithms for bleeding risk stratification. In patients with overt disseminated intravascular coagulation, therapeutic measures should strictly follow clinical symptoms. An acquired von Willebrand syndrome may evoke a severe bleeding tendency in patients with myeloproliferative neoplasms or plasma cell dyscrasias. In 15% of cases, acquired hemophilia A, due to the formation of inhibitory autoantibodies against coagulation factor VIII, is associated with malignancy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Dermatologie (Heidelberg, Germany) - 73(2022), 10 vom: 14. Okt., Seite 809-819 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Gerinnungsstörungen bei Tumorerkrankungen |
|---|
| Beteiligte Personen: |
Voigtländer, Minna [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.09.2022 Date Revised 28.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00105-022-05056-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346197732 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346197732 | ||
| 003 | DE-627 | ||
| 005 | 20231226030838.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00105-022-05056-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM346197732 | ||
| 035 | |a (NLM)36102956 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Voigtländer, Minna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cancer-associated coagulation disorders |
| 246 | 3 | 3 | |a Gerinnungsstörungen bei Tumorerkrankungen |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2022 | ||
| 500 | |a Date Revised 28.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Diagnosis and treatment of paraneoplastic coagulation disorders are a challenge in daily practice. While prophylactic anticoagulation to prevent venous thromboembolism (VTE) is standard of care in all surgical and acutely ill medical cancer patients, particularly careful evaluation of risks and benefits using validated risk assessment models is required during outpatient chemotherapy. Low-molecular-weight heparin and direct oral factor Xa inhibitors are available to treat established cancer-associated VTE, adhering to algorithms for bleeding risk stratification. In patients with overt disseminated intravascular coagulation, therapeutic measures should strictly follow clinical symptoms. An acquired von Willebrand syndrome may evoke a severe bleeding tendency in patients with myeloproliferative neoplasms or plasma cell dyscrasias. In 15% of cases, acquired hemophilia A, due to the formation of inhibitory autoantibodies against coagulation factor VIII, is associated with malignancy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticoagulants | |
| 650 | 4 | |a Disseminated intravascular coagulation | |
| 650 | 4 | |a Hemophilia A, acquired | |
| 650 | 4 | |a Venous thromboembolism | |
| 650 | 4 | |a Von Willebrand disease, acquired | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a Factor VIII |2 NLM | |
| 650 | 7 | |a 9001-27-8 |2 NLM | |
| 700 | 1 | |a Langer, Florian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatologie (Heidelberg, Germany) |d 2022 |g 73(2022), 10 vom: 14. Okt., Seite 809-819 |w (DE-627)NLM330027379 |x 2731-7013 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2022 |g number:10 |g day:14 |g month:10 |g pages:809-819 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00105-022-05056-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2022 |e 10 |b 14 |c 10 |h 809-819 | ||